Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.09 and traded as high as $3.86. Achieve Life Sciences shares last traded at $3.81, with a volume of 235,411 shares.
Achieve Life Sciences Stock Down 36.5%
The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $77.36 million, a PE ratio of -1.66 and a beta of 1.63. The firm has a 50-day moving average of $3.03 and a two-hundred day moving average of $3.06.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). On average, equities research analysts forecast that Achieve Life Sciences, Inc. will post -1.17 EPS for the current year.
Hedge Funds Weigh In On Achieve Life Sciences
Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its holdings in Achieve Life Sciences by 185.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 4,905 shares during the last quarter. Sigma Planning Corp bought a new position in Achieve Life Sciences during the 4th quarter worth approximately $37,000. AQR Capital Management LLC bought a new position in Achieve Life Sciences in the first quarter worth about $32,000. ADAR1 Capital Management LLC lifted its holdings in Achieve Life Sciences by 14,375.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 13,173 shares of the biopharmaceutical company's stock worth $46,000 after acquiring an additional 13,082 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in Achieve Life Sciences in the fourth quarter valued at approximately $49,000. Institutional investors own 33.52% of the company's stock.
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
